NASHVILLE, Tenn.--(BUSINESS WIRE)--Revance Therapeutics (Nasdaq: RVNC), a biotechnology company focused on innovative aesthetic and therapeutic offerings, today announced the company will present an ...

DaxibotulinumtoxinA for Injection for treatment for cervical dystonia met the primary and all secondary endpoints in the phase 3 ASPEN-1 study, according to topline results released today by Revance ...

After debuting in the aesthetics market with Daxxify last year, Revance has made its way to the potentially lucrative therapeutic space. With a Monday FDA nod to treat cervical dystonia in adults, ...

The US Food and Drug Administration (FDA) has expanded the indiction for daxibotulinumtoxinA-lanm injection (Daxxify, Revance Therapeutics) for the treatment of cervical dystonia in adults, the ...

NASHVILLE, Tenn.--(BUSINESS WIRE)--Revance Therapeutics, Inc. (Nasdaq: RVNC) a biotechnology company focused on innovative aesthetic and therapeutic offerings, today announced that it has submitted a ...

Dystonias are potentially disabling neurological conditions that can greatly affect quality of life. Effective treatments are sparse, with botulinum toxin (Botox) injections into the affected muscles ...

Recently published Cervical Dystonia Market Insights report includes a comprehensive understanding of current treatment practices, cervical dystonia emerging drugs, market share of individual ...

Shares of Revance Therapeutics Inc. RVNC gained 8% premarket on Monday after the U.S. Food and Drug Administration approved the biotech company’s Daxxify injection for treatment of cervical dystonia ...

Recent discoveries made by researchers from Charité – Universitätsmedizin Berlin may prove vital in improving the treatment of dystonia, a neurological movement disorder. Published in PNAS, their ...

Dystonias are potentially disabling neurological conditions that can greatly affect quality of life. Effective treatments are sparse, with botulinum toxin (Botox) injections into the affected muscles ...

The cervical dystonia market is expected to increase due to an increase in disease prevalence during the forecast period. Additionally, the expected launch of emerging therapies such as ABP-450 ...